Companies › Pyxis Oncology
2 active drug programs in 3 registered trials: 3 Phase 1; Oncology; next expected readout Apr 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| PYX-201 Antibody-drug conjugate | – | Phase 1 | Solid Tumor; Advanced Solid Tumors | Apr 2027 |
| PYX-106 | – | Phase 1 | Solid Tumor | – |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT05718557 | PYX-106 | Phase 1 | Solid Tumor | Oncology | May 2026 |
| NCT05720117 | PYX-201 | Phase 1 | Solid Tumor | Oncology | Apr 2027 |
| NCT06795412 | PYX-201 | Phase 1 | Advanced Solid Tumors | Oncology | Dec 2027 |
Cash and short-term investments of $56m on 2026-09-30; operating cash outflow about $81m a year; runway about 8 months at that burn, to Jun 2027
Press releases filed as 8-K in the last year:
Held by 2 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.
No annotated target.
–
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.